Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorDe Laurentiis, M.
dc.contributor.authorMerino, L. de la Cruz
dc.contributor.authorHart, L.
dc.contributor.authorBardia, A.
dc.contributor.authorIm, S-A.
dc.contributor.authorSohn, J.
dc.contributor.authorNeven, P.
dc.contributor.authorMartin, M.
dc.contributor.authorJi, Y.
dc.contributor.authorYang, S.
dc.contributor.authorHu, H.
dc.contributor.authorLteif, A.
dc.contributor.authorTripathy, D.
dc.contributor.authoraffiliation[De Laurentiis, M.] Fdn G Pascale, IRCCS Ist Nazl Tumori, Naples, Italy
dc.contributor.authoraffiliation[Merino, L. de la Cruz] Hosp Univ Virgen Macarena, Dept Med, Seville, Spain
dc.contributor.authoraffiliation[Hart, L.] Florida Canc Specialists, Sarah Cannon Res Inst, Ft Myers, FL USA
dc.contributor.authoraffiliation[Bardia, A.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
dc.contributor.authoraffiliation[Im, S-A.] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul Natl Univ Hosp, Seoul, South Korea
dc.contributor.authoraffiliation[Sohn, J.] Yonsei Univ, Yonsei Canc Ctr, Seoul, South Korea
dc.contributor.authoraffiliation[Neven, P.] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Campus Gasthuisberg, Leuven, Belgium
dc.contributor.authoraffiliation[Martin, M.] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Ctr Invest Biomed Red Canc, Grp Espanol Invest Canc Mama, Madrid, Spain
dc.contributor.authoraffiliation[Ji, Y.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Yang, S.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Hu, H.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Lteif, A.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA
dc.contributor.authoraffiliation[Tripathy, D.] Univ Texas MD Anderson Canc Ctr, Oncol, Houston, TX 77030 USA
dc.contributor.funderNovartis Pharmaceuticals Corporation
dc.date.accessioned2025-01-07T16:00:43Z
dc.date.available2025-01-07T16:00:43Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.433
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420404296/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27555
dc.identifier.wosID573469100331
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.page.numberS378-S379
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleImpact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen del Rocío
SAS - Hospital Universitario Virgen Macarena

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía